NCT00275132View on ClinicalTrials.gov

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

670

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

Tarceva (OSI-774, erlotinib) PO 150 mg daily

DRUG

Matched placebo

Matched placebo PO daily

Trial Locations (1)

NW1 2ND

London Lung Cancer Group, London

Sponsors

Collaborators (1)

Cancer Research UK
All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

Roche Pharma AG

INDUSTRY

lead

University College, London

OTHER